UNSPSC 51333006: Molindone hydrochloride

This classification denotes an antipsychotic agent with the molecular formula C16H24N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1DWS68PNE6, chemically known as 4h-indol-4-one, 3-ethyl-1,5,6,7-tetrahydro-2-methyl-5-(4-morpholinylmethyl)-, monohydrochloride but more generally known as molindone hydrochloride, which bears US NIH Compound Identifier 27421. European Medicines Agency schedules Molindone hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14587MIG.

UNSPSC 51333006 Molindone hydrochloride is a Commodity code for a specific antipsychotic pharmaceutical product, but recent state and local procurement activity under this code shows minimal volume. The only documented solicitation targets naloxone and drug deactivation systems rather than molindone, representing a significant mismatch between the code's pharmaceutical scope and actual buying patterns. State and local health departments, counties, and community health agencies use this code family to procure medications and medical supplies, but molindone hydrochloride itself does not appear in current market activity at the state and local level. Issuing bodies under related pharmaceutical procurement codes typically include county health departments, state health agencies, and special-purpose health districts, though the sourced opportunity reflects county-level procurement.

Seminole County, Florida, posted an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, for naloxone and drug deactivation systems with a response deadline of July 26, 2023, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement called for 1,900 units of naloxone and 800 safe drug deactivation systems annually under an initial two-year term with a one-year renewal option. Bidders were required to submit electronically through the county's e-Procurement Portal, include all shipping and delivery costs in their proposals, provide drug-free workplace certification, and meet E-Verify compliance. The contract included a three-month probationary period and potential FEMA funding, introducing federal compliance requirements. The code shows limited recent activity; firms pursuing state and local pharmaceutical procurement should monitor higher-tier family and class codes for broader solicitation signals.